Skip to content

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

We are honoured to announce that our esteemed advisor, Prof. Dr. Petter Brodin, has launched the “imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)” study in partnership with Karolinska University Hospital and Pfizer.

This groundbreaking study aims to investigate the efficacy of orally administered nirmatrelvir/ritonavir in improving the quality of life for non-hospitalized adult participants suffering from post-acute COVID-19 syndrome (PACS). Currently, there is no curative treatment for PACS, and the focus is on symptom management and personalized rehabilitation.

Petter Brodin’s interventional, randomized, and placebo-controlled clinical intervention trial will evaluate the potential benefits of nirmatrelvir/ritonavir (Paxlovid®) compared to placebo/ritonavir. The study will enrol 400 patients with severe PACS, identified from a database of 988 patients who have received comprehensive clinical and laboratory examinations at the Karolinska University Hospital Post-COVID clinics since May 2020.

In addition to assessing the impact on patients’ quality of life, the study includes deep exploratory systems-level analyses of the immune system in PACS patients, investigating the changes induced by nirmatrelvir/ritonavir treatment. This research holds significant promise in addressing the unmet medical needs of non-hospitalized patients with post-COVID, shedding light on potential long-term solutions.

We extend our deepest gratitude to Petter Brodin for his invaluable contribution to the field of long COVID research. His dedication and expertise in the study’s design and implementation will undoubtedly advance our understanding and provide new hope for individuals suffering from this challenging condition.

Stay tuned for updates as we eagerly follow the progress of the PROLIFIC study and its potential impact on improving the lives of post-COVID patients.

Read more about it below:

https://clinicaltrials.gov/ct2/show/NCT05823896 

#PROLIFICstudy #LongCOVID #ResearchInnovation #MedicalBreakthrough #QualityofLife #ProudAdvisor

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Recent News

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

Recent News

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

Inside Scailyte - Episode 8: Meet Sajid Maqbool

Meet Sajid Maqbool, our Information Technology Engineer at Scailyte AG. In our latest episode of "In...

Read more

Recent News

Inside Scailyte – Episode 7: Meet Anna Dimitrova

Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...

Read more

Recent News

ScaiPod: Revolutionizing Immuno-Oncology With Multi-Omics and AI at Scale

ScaiPod's mission is clear: develop next-generation clinical biomarkers for precise immuno-oncology ...

Read more

Recent News

01 /04

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Recent News

02 /04

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

Recent News

03 /04

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Inside Scailyte - Episode 8: Meet Sajid Maqbool

Meet Sajid Maqbool, our Information Technology Engineer at Scailyte AG. In our latest episode of "In...

Read more

Recent News

04 /04

Inside Scailyte – Episode 7: Meet Anna Dimitrova

Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...

Read more

ScaiPod: Revolutionizing Immuno-Oncology With Multi-Omics and AI at Scale

ScaiPod's mission is clear: develop next-generation clinical biomarkers for precise immuno-oncology ...

Read more

Recent News